+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alpha Glucosidase Inhibitors Market - Global Forecast 2025-2030- Product Image
Alpha Glucosidase Inhibitors Market - Global Forecast 2025-2030- Product Image
Sale

Alpha Glucosidase Inhibitors Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5675041
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Alpha Glucosidase Inhibitors Market is undergoing dynamic transformation as innovation, shifting trade policy, and increasing diabetes prevalence shape new pathways for growth. Senior decision-makers require a comprehensive, actionable overview of evolving market opportunities and competitive pressures within this vital therapeutic domain.

Market Snapshot: Alpha Glucosidase Inhibitors Market Size and Growth

The Alpha Glucosidase Inhibitors Market grew from USD 703.76 million in 2024 to USD 809.36 million in 2025. It is expected to continue growing at a CAGR of 14.59%, reaching USD 1.59 billion by 2030. This robust trajectory reflects rising rates of type 2 diabetes, sustained advancements in manufacturing, and an expanding focus on patient-centered formulation strategies.

Scope & Segmentation

The report provides an in-depth evaluation of the alpha-glucosidase inhibitors landscape, including the following segmentation and focus areas:

  • Product Types: Acarbose, Miglitol, Voglibose
  • Dosage Forms: Capsules (Hard Gel, Softgel), Oral Solutions (Suspension, Syrup), Tablets (Extended Release, Film Coated)
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Treatment Modalities: Combination Therapy, Monotherapy
  • Patient Age Groups: Adult, Geriatric, Pediatric
  • Key Regions: Americas, Europe, Middle East & Africa, Asia-Pacific
  • Country and Sub-Regional Analysis: United States (with state-level breakdowns), Canada, major markets across Latin America, Europe, the Middle East, Africa, and Asia-Pacific
  • Company Profiles: Bayer AG, Pfizer Inc., Novartis AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Limited, Astellas Pharma Inc., Zydus Cadila Limited, Teva Pharmaceutical Industries Limited

Technological Drivers

  • Formulation Innovations: Extended-release forms, film-coated tablets, bioadhesive capsules
  • Digital Health Integration: Glucose monitoring, telehealth, digital adherence platforms

Key Takeaways for Senior Decision-Makers

  • Extended-release and alternative dosage technologies are reshaping patient access, improving adherence among pediatric and geriatric populations, and diversifying clinical applications.
  • Stakeholders face new challenges and opportunities as the market shifts toward combination therapies and digital integration, requiring portfolio alignment and data-driven product development.
  • Competitive dynamics are being redefined through collaborations between established pharmaceutical firms and emerging biotechs, targeting next-generation enzyme selectivity and improved side effect profiles.
  • Regional diversification strategies now play a critical role in mitigating market risks and capturing high-growth opportunities, especially in rapidly developing Asia-Pacific and emerging Latin American economies.
  • The demand for robust health-economic data is increasing as value-based reimbursement frameworks take precedence, emphasizing the strategic importance of real-world evidence generation.

Impact of US Tariff Revisions on Supply Chains and Pricing

Recent tariff adjustments in the United States have directly influenced the alpha-glucosidase inhibitors market, elevating costs for imported active pharmaceutical ingredients and finished formulations. Companies are reassessing sourcing models, entering long-term supplier contracts, and exploring domestic manufacturing initiatives to maintain pricing stability and supply continuity. Effective monitoring of policy shifts and agile adaptation to trade dynamics can enhance competitive positioning while mitigating operational risks.

Methodology & Data Sources

This report employs a structured research methodology combining secondary reviews of scientific literature, regulatory documents, and proprietary databases with primary interviews conducted among endocrinologists, regulatory experts, and supply chain specialists. All findings undergo triangulation, with statistical validation applied to scenario planning and risk quantification. Stringent quality assurance measures underpin the credibility of this analysis.

Why This Report Matters for Strategy and Growth

  • Equips senior leaders with actionable insights to drive product innovation, optimize operational strategy, and capitalize on evolving patient needs.
  • Enables organizations to anticipate regulatory challenges, implement supply chain resilience measures, and respond adaptively to changing trade policy and pricing structures.
  • Supports strategic planning across global and regional teams, identifying opportunity areas for technology integration and partnership development.

Conclusion

Senior decision-makers gain the clarity needed to navigate shifting therapeutic, regulatory, and economic dynamics in the alpha-glucosidase inhibitors market. Leveraging data-driven insights and agile strategies will be critical for growth and long-term market relevance.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of novel second-generation alpha glucosidase inhibitors in type 2 diabetes management across emerging Asian markets
5.2. Impact of intellectual property expiries on generic miglitol production and competitive pricing strategies in North America
5.3. Advancements in targeted drug delivery systems enhancing acarbose bioavailability and reducing gastrointestinal side effects
5.4. Emerging clinical trial outcomes evaluating alpha glucosidase inhibitor combinations with SGLT2 inhibitors for improved glycemic control
5.5. Regulatory landscape evolution for fast track orphan designation of alpha glucosidase inhibitors in rare glycogen storage diseases
5.6. Strategic partnerships between biotechnology startups and Big Pharma driving innovation in alpha glucosidase inhibitor pipeline diversification
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Alpha Glucosidase Inhibitors Market, by Product Type
8.1. Introduction
8.2. Acarbose
8.3. Miglitol
8.4. Voglibose
9. Alpha Glucosidase Inhibitors Market, by Dosage Form
9.1. Introduction
9.2. Capsules
9.2.1. Hard Gel
9.2.2. Softgel
9.3. Oral Solution
9.3.1. Suspension
9.3.2. Syrup
9.4. Tablets
9.4.1. Extended Release
9.4.2. Film Coated
10. Alpha Glucosidase Inhibitors Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Alpha Glucosidase Inhibitors Market, by Treatment Modality
11.1. Introduction
11.2. Combination Therapy
11.3. Monotherapy
12. Alpha Glucosidase Inhibitors Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Americas Alpha Glucosidase Inhibitors Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Alpha Glucosidase Inhibitors Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Alpha Glucosidase Inhibitors Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bayer AG
16.3.2. Pfizer Inc.
16.3.3. Novartis AG
16.3.4. Sanofi S.A.
16.3.5. Takeda Pharmaceutical Company Limited
16.3.6. Bristol-Myers Squibb Company
16.3.7. Dr. Reddy's Laboratories Limited
16.3.8. Astellas Pharma Inc.
16.3.9. Zydus Cadila Limited
16.3.10. Teva Pharmaceutical Industries Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ALPHA GLUCOSIDASE INHIBITORS MARKET: RESEARCHAI
FIGURE 26. ALPHA GLUCOSIDASE INHIBITORS MARKET: RESEARCHSTATISTICS
FIGURE 27. ALPHA GLUCOSIDASE INHIBITORS MARKET: RESEARCHCONTACTS
FIGURE 28. ALPHA GLUCOSIDASE INHIBITORS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ALPHA GLUCOSIDASE INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ACARBOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ACARBOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MIGLITOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MIGLITOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY VOGLIBOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY VOGLIBOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HARD GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HARD GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SOFTGEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SOFTGEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SYRUP, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SYRUP, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY FILM COATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY FILM COATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 104. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 105. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 106. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 107. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 108. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 109. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 110. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 111. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 114. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 115. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 116. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 117. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 118. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 119. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 120. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 121. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 122. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 123. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 124. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 125. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 130. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 131. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 132. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 199. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 202. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 203. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 204. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 205. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 206. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 207. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 212. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 213. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 214. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 215. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 216. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 217. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 218. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 219. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 220. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 221. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 222. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 223. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 228. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 229. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 247. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 248. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 249. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 250. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 251. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 252. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 253. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 254. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 255. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 256. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 257. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 260. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 261. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 262. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 263. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 265. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 266. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 267. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 268. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 269. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 270. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 271. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 276. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 277. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 278. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ORAL SOLUTION, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (US

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Alpha Glucosidase Inhibitors market report include:
  • Bayer AG
  • Pfizer Inc.
  • Novartis AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • Dr. Reddy's Laboratories Limited
  • Astellas Pharma Inc.
  • Zydus Cadila Limited
  • Teva Pharmaceutical Industries Limited

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 809.36 Million
Forecasted Market Value ( USD ) by 2030 $ 1590 Million
Compound Annual Growth Rate14.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Alpha Glucosidase Inhibitors: Market Share, and Growth Analysis by Product Type (Acarbose, Miglitol, Voglibose), Application, End User, Technology - Product Image

Alpha Glucosidase Inhibitors: Market Share, and Growth Analysis by Product Type (Acarbose, Miglitol, Voglibose), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Alpha Glucosidase Inhibitors Market Report 2025 - Product Image

Alpha Glucosidase Inhibitors Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Alpha Glucosidase Inhibitors - Global Strategic Business Report - Product Image

Alpha Glucosidase Inhibitors - Global Strategic Business Report

  • Report
  • 285 Pages
  • Global
From
Alpha Glucosidase Inhibitor - Pipeline Insight, 2025 - Product Image

Alpha Glucosidase Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
a-Glucosidase Inhibitors Market - Global Forecast 2025-2030 - Product Image

a-Glucosidase Inhibitors Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.